GLOBALT Investments LLC GA Has $4.50 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

GLOBALT Investments LLC GA grew its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 20.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 48,659 shares of the biopharmaceutical company's stock after purchasing an additional 8,204 shares during the period. GLOBALT Investments LLC GA's holdings in Gilead Sciences were worth $4,495,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in GILD. Swedbank AB lifted its position in Gilead Sciences by 10.2% during the 3rd quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company's stock valued at $171,672,000 after purchasing an additional 189,622 shares during the period. OneDigital Investment Advisors LLC lifted its position in Gilead Sciences by 5.1% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 32,416 shares of the biopharmaceutical company's stock valued at $2,718,000 after purchasing an additional 1,580 shares during the period. Coastline Trust Co acquired a new position in Gilead Sciences during the 3rd quarter valued at about $122,000. Natixis Advisors LLC lifted its position in Gilead Sciences by 18.1% during the 3rd quarter. Natixis Advisors LLC now owns 169,363 shares of the biopharmaceutical company's stock valued at $14,199,000 after purchasing an additional 25,912 shares during the period. Finally, KPP Advisory Services LLC acquired a new position in Gilead Sciences during the 3rd quarter valued at about $206,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 17,929 shares of Gilead Sciences stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the sale, the chief financial officer now directly owns 169,061 shares of the company's stock, valued at approximately $19,977,938.37. This trade represents a 9.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 302,785 shares of company stock worth $30,503,250 over the last 90 days. Insiders own 0.29% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on GILD. JPMorgan Chase & Co. upped their price target on Gilead Sciences from $105.00 to $115.00 and gave the company an "overweight" rating in a research note on Wednesday, January 29th. Wells Fargo & Company upped their price target on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Piper Sandler upped their price target on Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. BMO Capital Markets increased their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 12th. Finally, Oppenheimer increased their target price on Gilead Sciences from $115.00 to $132.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 4th. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $104.52.

Gilead Sciences Stock Performance

GILD stock traded down $1.64 during trading hours on Thursday, hitting $105.87. 11,112,609 shares of the stock were exchanged, compared to its average volume of 6,724,778. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $131.84 billion, a P/E ratio of 286.14, a P/E/G ratio of 0.71 and a beta of 0.21. The company has a 50-day simple moving average of $103.00 and a two-hundred day simple moving average of $93.47. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.98%. The ex-dividend date is Friday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's payout ratio is currently 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.